Vyleesi (Bremelanotide) Adult Dosing: Complete Guide for Women Ages 30 to 49

What is the standard Vyleesi dose for women in their 30s and 40s?

Bremelanotide is approved as Vyleesi, a 1.75 mg subcutaneous injection delivered with a prefilled autoinjector, prescription only [1][2]. The label gives one dose for every patient: 1.75 mg into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity [1].

The label's dosing section does not vary with age [1]. The two trials behind the approval enrolled women aged 19 to 56 with a mean age of 39, so the 30 to 49 range sits in the middle of the studied group [1][3].

What the label keys on is menopausal status, not age. The approved use is premenopausal women with acquired, generalized hypoactive sexual desire disorder — low desire that causes marked distress or interpersonal difficulty and is not due to a medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label states Vyleesi is not indicated for postmenopausal women or for men, and not to enhance sexual performance [1]. A 49-year-old who is still premenopausal falls inside the labeled population; a 45-year-old who is postmenopausal does not [1].

How far ahead, and how often?

The label says to inject at least 45 minutes before anticipated sexual activity, and adds that the optimal window has not been fully characterized and that the duration of effect after a dose is unknown [1]. Patients are told they can choose the timing based on how they experience the duration of effect on desire and on adverse reactions such as nausea [1].

Two limits apply. The label says not to give more than one dose within 24 hours, and says more than 8 doses per month is not recommended [1]. The label gives its reasons. The efficacy of consecutive doses within 24 hours has not been established, and doses given close together may increase the risk of additive blood-pressure effects [1]. For the monthly recommendation, few patients in the phase 3 program used more than 8 doses a month, and more frequent dosing raises the risk of focal hyperpigmentation and lengthens the time each month that blood pressure is elevated [1]. Most patients in the trials used Vyleesi two to three times per month and no more than once a week [1].

The label recommends discontinuing Vyleesi after 8 weeks if symptoms have not improved [1].

What the trials showed at 1.75 mg

Two identical phase 3 trials (RECONNECT 301 and 302) randomized 1,267 premenopausal women with HSDD 1:1 to bremelanotide 1.75 mg as needed or placebo for 24 weeks; 1,247 women were in the safety population and 1,202 in the efficacy analysis, with a mean age of 39 [3][1].

Compared with placebo, the Female Sexual Function Index desire domain score improved by 0.30 points in study 301 and 0.42 in study 302, and by 0.35 across the integrated studies, all with P<0.001 [3]. Desire-related distress on the FSDS-DAO item 13 fell by 0.37, 0.29 and 0.33 points [3]. In the Vyleesi label, desire scores changed by 0.5 with Vyleesi versus 0.2 with placebo in study 1, and 0.6 versus 0.2 in study 2 [1].

The trials found improvements in desire and desire-related distress scores, but no significant difference in the number of satisfying sexual events [3]. In the pooled trials, 18% of women on Vyleesi stopped because of adverse reactions versus 2% on placebo, most often for nausea (8%), headache (2%), vomiting (1%), flushing (1%) or injection site reactions (1%) [1].

Does weight, kidney function or liver function change the dose?

The label's dosing section gives the single 1.75 mg dose with no weight-based adjustment [1]. Its pharmacokinetic section reports higher exposure in organ impairment: area under the curve rises 1.5-fold in moderate and 2-fold in severe renal impairment, and 1.2-fold in mild and 1.7-fold in moderate hepatic impairment [1].

After a 1.75 mg subcutaneous dose, mean peak plasma concentration is 72.8 ng/mL, median time to peak is about 1 hour, absolute bioavailability is about 100%, and mean terminal half-life is about 2.7 hours (range 1.9 to 4.0) [1].

Blood pressure and heart rate after each dose

The label reports that Vyleesi produced maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart rate reduction of up to 5 beats per minute; values usually returned to baseline within 12 hours [1]. Those are maximal, not average, figures. In a separate open-label ambulatory monitoring study of 127 premenopausal women dosed once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4), with a mean heart rate decrease of 0.5 beats per minute [1]. No additive effect on blood pressure or heart rate was seen with repeat daily dosing 24 hours apart for up to 16 days [1].

The label lists uncontrolled hypertension or known cardiovascular disease as contraindications and does not recommend Vyleesi for patients at high risk of cardiovascular disease [1]. It asks that cardiovascular risk be considered before starting and periodically during treatment, and that blood pressure be well controlled [1].

Side effects that shape how the drug is used

Nausea is the dominant one: 40.0% on Vyleesi versus 1.3% on placebo [1]. It was highest after the first dose, reported by 21% of patients, then declined to about 3% after later doses; median onset was within one hour and it lasted about two hours [1]. Thirteen percent of Vyleesi patients used an anti-nausea medicine and 8% stopped the trials because of nausea [1].

In one single-dose study, taking oral ondansetron before Vyleesi did not significantly reduce nausea; the label does not recommend that pretreatment [1]. In that phase 4 study, 228 healthy women were randomized to 8 mg oral ondansetron or placebo 30 minutes before a 1.75 mg dose, and the incidence of nausea did not differ significantly [1]. The label adds that ondansetron given after the dose or after nausea starts has not been formally studied [1].

Focal hyperpigmentation — darkening of skin, gums or breasts, including the face — was reported by 1% of patients who received up to 8 doses a month, versus none on placebo [1]. In another study, 38% of patients developed it after daily dosing for 8 days, and a further 14% after 8 more consecutive days [1]. Risk is higher in patients with darker skin and with daily dosing, and resolution was not confirmed in all patients after the drug was stopped; the label says to consider discontinuing if it develops [1].

Other common reactions in the pooled trials, Vyleesi versus placebo: flushing 20.3% versus 0.3%, injection site reactions 13.2% versus 8.4%, headache 11.3% versus 1.9% [1].

What should not be combined with a dose

The label says to avoid Vyleesi with oral naltrexone products intended to treat alcohol or opioid addiction, because Vyleesi may significantly decrease naltrexone blood levels and the consequence of treatment failure is severe [1]. Vyleesi may also slow gastric emptying, so the label says to avoid it when taking oral drugs that depend on threshold concentrations for efficacy, such as antibiotics, and to consider skipping a dose when a quick effect from an oral medicine is wanted, such as indomethacin [1].

Alcohol was tested: in a crossover study of 24 healthy volunteers, 0.6 g/kg of alcohol did not change bremelanotide blood levels, and flushing and headache rates with the combination were similar to the higher of the two single-agent rates [1]. That study used a 20 mg intranasal dose, which produces about 2.5-fold the peak concentration of Vyleesi [1].

On pregnancy, the label advises stopping Vyleesi if pregnancy is suspected and using effective contraception during treatment; in dogs, fetal harm occurred at exposures at least 16 times the human dose by area under the curve [1]. The label's pregnancy section was being revised by an October 22, 2026 labeling supplement [4].

Is PT-141 the same as Vyleesi?

PT-141 products sold as compounded or research-use peptides are not Vyleesi and are not FDA-approved drugs, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [5][1]. The 1.75 mg dose is the Vyleesi label's dose and applies to Vyleesi, not to other PT-141 products [1].